| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
|
Nat Med
|
2004
|
6.46
|
|
2
|
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
|
Nat Med
|
2003
|
4.64
|
|
3
|
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection.
|
Immunity
|
2005
|
3.62
|
|
4
|
Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.
|
Am J Trop Med Hyg
|
2005
|
2.77
|
|
5
|
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
|
Clin Infect Dis
|
2011
|
2.71
|
|
6
|
Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.
|
J Infect Dis
|
2005
|
2.66
|
|
7
|
Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria.
|
Proc Natl Acad Sci U S A
|
2008
|
2.62
|
|
8
|
Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
|
Infect Immun
|
2009
|
2.57
|
|
9
|
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
|
Proc Natl Acad Sci U S A
|
2005
|
2.57
|
|
10
|
MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
|
PLoS One
|
2009
|
2.49
|
|
11
|
Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density.
|
Malar J
|
2006
|
2.39
|
|
12
|
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
|
PLoS Clin Trials
|
2006
|
2.33
|
|
13
|
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.
|
J Immunol
|
2005
|
2.19
|
|
14
|
Prime-boost vectored malaria vaccines: progress and prospects.
|
Hum Vaccin
|
2010
|
2.12
|
|
15
|
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
|
Infect Immun
|
2009
|
2.08
|
|
16
|
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.
|
J Immunol
|
2005
|
2.03
|
|
17
|
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.
|
Nat Commun
|
2013
|
1.95
|
|
18
|
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
|
Mol Ther
|
2011
|
1.92
|
|
19
|
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
|
J Infect Dis
|
2012
|
1.85
|
|
20
|
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
|
Clin Infect Dis
|
2012
|
1.82
|
|
21
|
Effective induction of high-titer antibodies by viral vector vaccines.
|
Nat Med
|
2008
|
1.76
|
|
22
|
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
|
Mol Ther
|
2012
|
1.76
|
|
23
|
Progression of Plasmodium berghei through Anopheles stephensi is density-dependent.
|
PLoS Pathog
|
2007
|
1.71
|
|
24
|
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
|
PLoS Med
|
2004
|
1.70
|
|
25
|
Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes.
|
J Immunol
|
2006
|
1.62
|
|
26
|
Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.
|
Immunology
|
2004
|
1.61
|
|
27
|
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
|
PLoS One
|
2012
|
1.58
|
|
28
|
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
|
J Infect Dis
|
2004
|
1.58
|
|
29
|
Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
|
J Immunol
|
2010
|
1.55
|
|
30
|
Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.
|
J Immunol
|
2004
|
1.51
|
|
31
|
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
|
PLoS One
|
2008
|
1.51
|
|
32
|
Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
|
Eur J Immunol
|
2008
|
1.50
|
|
33
|
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
|
Vaccine
|
2006
|
1.48
|
|
34
|
Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass.
|
Sci Transl Med
|
2010
|
1.46
|
|
35
|
The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum.
|
J Immunol
|
2007
|
1.38
|
|
36
|
Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes.
|
Proc Natl Acad Sci U S A
|
2006
|
1.36
|
|
37
|
Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.
|
Cell Host Microbe
|
2009
|
1.36
|
|
38
|
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
|
Infect Immun
|
2006
|
1.30
|
|
39
|
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
|
PLoS One
|
2011
|
1.27
|
|
40
|
Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
|
Vaccine
|
2006
|
1.25
|
|
41
|
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
|
Vaccine
|
2011
|
1.25
|
|
42
|
Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
|
Clin Infect Dis
|
2006
|
1.25
|
|
43
|
A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
|
PLoS One
|
2012
|
1.24
|
|
44
|
Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
|
PLoS One
|
2008
|
1.23
|
|
45
|
Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance.
|
J Immunol
|
2005
|
1.22
|
|
46
|
Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
|
PLoS One
|
2011
|
1.22
|
|
47
|
Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
|
Vaccine
|
2010
|
1.21
|
|
48
|
Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area.
|
Am J Trop Med Hyg
|
2007
|
1.20
|
|
49
|
Competition between CTL narrows the immune response induced by prime-boost vaccination protocols.
|
J Immunol
|
2002
|
1.18
|
|
50
|
A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
|
Proc Natl Acad Sci U S A
|
2003
|
1.18
|
|
51
|
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.
|
Int J Cancer
|
2005
|
1.18
|
|
52
|
Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
|
PLoS One
|
2007
|
1.17
|
|
53
|
The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.
|
J Immunol
|
2011
|
1.17
|
|
54
|
Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity.
|
J Immunol
|
2005
|
1.17
|
|
55
|
Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection.
|
J Infect Dis
|
2013
|
1.12
|
|
56
|
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
|
PLoS One
|
2013
|
1.09
|
|
57
|
Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.
|
J Immunol
|
2011
|
1.07
|
|
58
|
A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
|
PLoS One
|
2012
|
1.06
|
|
59
|
Characterization of the fine specificity of bovine CD8 T-cell responses to defined antigens from the protozoan parasite Theileria parva.
|
Infect Immun
|
2007
|
1.04
|
|
60
|
Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area.
|
Eur J Immunol
|
2006
|
1.01
|
|
61
|
Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals.
|
Infect Immun
|
2006
|
0.99
|
|
62
|
Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.
|
PLoS One
|
2012
|
0.97
|
|
63
|
Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
|
Sci Rep
|
2013
|
0.94
|
|
64
|
Dual neonate vaccine platform against HIV-1 and M. tuberculosis.
|
PLoS One
|
2011
|
0.93
|
|
65
|
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
|
Hum Vaccin Immunother
|
2012
|
0.91
|
|
66
|
Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses.
|
Infect Immun
|
2003
|
0.91
|
|
67
|
Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
|
PLoS One
|
2013
|
0.89
|
|
68
|
A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis.
|
PLoS One
|
2007
|
0.88
|
|
69
|
Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.
|
Vaccine
|
2013
|
0.88
|
|
70
|
Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.
|
Eur J Immunol
|
2013
|
0.88
|
|
71
|
Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.
|
Biotechnol Bioeng
|
2011
|
0.88
|
|
72
|
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
|
Virol J
|
2013
|
0.87
|
|
73
|
Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice.
|
PLoS One
|
2013
|
0.86
|
|
74
|
Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
|
Vaccine
|
2004
|
0.86
|
|
75
|
Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
|
Vaccine
|
2012
|
0.86
|
|
76
|
A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression.
|
PLoS One
|
2013
|
0.86
|
|
77
|
Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
|
J Immunol
|
2012
|
0.85
|
|
78
|
Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.
|
Nanomedicine (Lond)
|
2014
|
0.85
|
|
79
|
Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines.
|
Vaccine
|
2009
|
0.84
|
|
80
|
The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.
|
Sci Rep
|
2013
|
0.84
|
|
81
|
Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.
|
J Virol Methods
|
2010
|
0.82
|
|
82
|
Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies.
|
Travel Med Infect Dis
|
2012
|
0.82
|
|
83
|
A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.
|
PLoS Negl Trop Dis
|
2013
|
0.81
|
|
84
|
Prime-boost immunisation against tropical theileriosis with two parasite surface antigens: evidence for protection and antigen synergy.
|
Vaccine
|
2011
|
0.81
|
|
85
|
Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA.
|
PLoS One
|
2012
|
0.80
|
|
86
|
T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.
|
Pediatr Infect Dis J
|
2012
|
0.80
|
|
87
|
Poxvirus vectors.
|
Vaccine
|
2013
|
0.80
|
|
88
|
Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis.
|
Immunol Cell Biol
|
2010
|
0.78
|
|
89
|
Inverse associations of human leukocyte antigen and malaria parasite types in two West African populations.
|
Infect Immun
|
2005
|
0.77
|
|
90
|
Incidental diagnosis in healthy clinical trial subjects.
|
Clin Transl Sci
|
2012
|
0.75
|
|
91
|
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.
|
Hum Vaccin Immunother
|
2013
|
0.75
|
|
92
|
Immunity, safety and protection of an Adenovirus 5 prime--Modified Vaccinia virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves.
|
Vet Res
|
2014
|
0.75
|
|
93
|
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.
|
Res Sq
|
2022
|
0.75
|
|
94
|
Influenza vaccines and immunopathology.
|
Expert Rev Vaccines
|
2012
|
0.75
|